Sentia Medical Sciences

Executive Summary

Sentia Medical Sciences is a private biotechnology company pioneering novel peptide therapeutics called astressins to block corticotropin-releasing factor (CRF) and urocortins, key mediators of the stress response. By targeting these pathways, Sentia aims to manage and potentially cure chronic stress-related diseases, including gastrointestinal and endocrine disorders. Founded in 2018 and based in San Diego, the company is in preclinical development with no disclosed milestones or funding history. Its approach leverages decades of research on CRF biology but faces significant technical and regulatory hurdles. If successful, Sentia could address a large unmet need in stress-driven conditions, though commercialization is years away. The company's low public profile suggests it may be seeking early-stage partnerships or financing to advance its lead candidate.

Upcoming Catalysts (preview)

• TBDLead Candidate IND Filing20% success
• TBDSeries A Financing or Partnership Announcement40% success
• TBDPreclinical Proof-of-Concept Data Release50% success